我要投票 千珍在医疗器械行业中的票数:560
· 外 推 电 报 ·
2026-01-09 16:14:52 星期五

【千珍是哪个国家的品牌?】

千珍是什么牌子?「千珍」是 广西千珍制药有限公司 旗下著名品牌。该品牌发源于广西南宁市,由创始人余平德在2004-06-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力千珍品牌出海!将品牌入驻外推网,定制千珍品牌推广信息,可以显著提高千珍产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

千珍(长安)制药是一个集天然药物研发、中药提取、生产、营销于一体的综合性现代化制药企业,公司总部位于国家第四个经济区北部湾核心城市南宁,目前拥有千珍制药(位于南宁)、长安制药(位于柳州融安县)两个具规模的中药现代化生产基地,其药品生产有40年历史,厂区按GMP标准设计建造,以绿色生态环境生产为标准,已建成中药提取、颗粒剂、片剂、胶囊剂、口服液、糖浆剂、酊剂、煎膏剂等生产基地。

千珍牌系列产品以治疗百姓家庭常见病为主体,拥有感冒止咳类、儿童类以及综合类等系列产品。系列产品分布感冒止咳良药的感冒止咳糖浆、止咳枇杷糖浆、川贝枇杷糖浆、二冬膏、板蓝根颗粒(无糖型)、蛇胆川贝液等产品;儿童专用药的山楂麦曲颗粒儿童装、小儿复方麻黄碱桔梗糖浆、大山楂颗粒儿童装、小儿化痰止咳颗粒等治疗儿童常见的消化不良、感冒咳嗽等症状;综合类产品拥有复方罗汉果止咳片、参芪首乌补汁、罗汉果玉竹颗粒、维C银翘片(薄膜衣片)、牛黄上清片、消炎利胆片、消炎片(薄膜衣片)等家庭日常用药。

千珍(长安)制药高度注重研发创新,公司在南宁设有产品研发中心,并与中国科学院上海药物研究所、韩国Chemizon药业技术公司等国内外专业药物研究机构结成的战略合作伙伴追随国家对中医民族药的开发与重视,千珍(长安)制药2009年整合资源以新形象面市,公司董事会决策推出“千珍品牌运作工程”——决心做老百姓心中的品牌药,对产品生产技术、产品用料、产品包装进行提升。


英文翻译:Qianzhen (Chang'an) Pharmaceutical Co., Ltd. is a comprehensive modern pharmaceutical enterprise integrating natural drug research and development, Chinese medicine extraction, production and marketing. Its headquarter is located in Nanning, the core city of Beibu Gulf, the fourth economic zone of China. At present, it has two large-scale modern production bases of Chinese medicine, qianzhen (Nanning) and Chang'an (Rongan County, Liuzhou) It has a history of 40 years. The factory is designed and built according to GMP standard, taking the production of green ecological environment as the standard, and has established the production bases of traditional Chinese medicine extraction, granules, tablets, capsules, oral liquids, syrups, tinctures, decoctions, etc. Qianzhen brand series products take the treatment of common diseases of common people's families as the main body, with cold and cough relief, children's and comprehensive series products. The series of products are mainly distributed in cold cough syrup, cough loquat syrup, Chuanbei loquat syrup, Erdong cream, Banlangen Granules (sugar free type), Hedan Chuanbei liquid and other products; children's special medicines such as hawthorn maiqu granules children's clothing, children's Compound Ephedrine and Platycodon syrup, big Hawthorn granules children's clothing, children's Huatan Zhike granules and other products to treat children's common dyspepsia Symptoms such as cold and cough; comprehensive products include compound Luohanguo cough tablet, shenqishouwu Buzhi, Luohanguo Yuzhu granules, vitamin C Yinqiao tablet (film coated tablet), Niuhuang Shangqing tablet, Xiaoyan Lidan tablet, Xiaoyan tablet (film coated tablet) and other household daily drugs. Qianzhen (Chang'an) pharmaceutical attaches great importance to R & D and innovation. The company has a product R & D center in Nanning, and strategic partners with Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences, Chemizon pharmaceutical technology company of South Korea and other professional pharmaceutical research institutions at home and abroad follow the country's development and attention to traditional Chinese medicine. In 2009, qianzhen (Chang'an) pharmaceutical integrated resources and launched a new image, The board of directors of the company decided to launch the "qianzhen brand operation project" - determined to be the brand medicine in the hearts of the common people, and improve the production technology, product materials and product packaging.

本文链接: https://www.waitui.com/brand/9fc58e1a7.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

福建铁路公司注册资本增至377.1亿,增幅约15%

36氪获悉,爱企查App显示,近日,福建铁路有限公司发生工商变更,注册资本由约328.1亿人民币增至约377.1亿人民币,增幅约15%。

15分钟前

日联科技:已完成收购SSTI 66%股权

36氪获悉,日联科技公告,公司全资子公司新加坡瑞泰已按照协议约定支付本次交易的股权收购款,并取得 SSTI 66%股权,本次股权交割已完成。

15分钟前

正海生物:公司取得医疗器械注册证

36氪获悉,正海生物公告,公司于近日取得国家药品监督管理局下发的《中华人民共和国医疗器械注册证》,产品名称为钙硅生物陶瓷口腔骨修复材料,注册证编号为国械注准20263170015,有效期至2031年1月6日。该产品适用于牙槽骨缺损修复,采用三维打印方式成型,具备定制化生产潜力。此注册证的取得将丰富公司口腔领域产品线,提升市场竞争力。但产品上市后实际销售情况取决于市场推广效果,对公司未来业绩的影响无法准确预测。

15分钟前

闲鱼:2025年二次元、追星与游戏用户总量已突破1.6亿

36氪获悉,《2025闲鱼次元年度报告》显示,截至2025年底,闲鱼二次元、追星与游戏用户总量已突破1.6亿,年度二次元消费人数同比增长47%,平台已成为年轻人兴趣消费的首选阵地。

15分钟前

绿地控股:预计2025年净亏损160亿元-190亿元

36氪获悉,绿地控股公告,预计2025年归属于母公司所有者的净利润为-190亿元到-160亿元。上年同期为-155.52亿元。受资产价格持续下行、公司加大促销去化力度、部分项目开发周期延长等多种因素的影响,基于谨慎性原则,公司对存在风险的存货拟计提减值准备;由于市场有效需求不足、社会预期偏弱,公司房地产业的结转规模、基建产业的营收规模同比均有较大幅度的下降,公司房地产业结转毛利率也同比下降,导致业绩进一步承压;房地产项目利息资本化减少,计入当期财务费用的利息支出增加。

15分钟前

本页详细列出关于千珍的品牌信息,含品牌所属公司介绍,千珍所处行业的品牌地位及优势。
咨询